| University of Strasbourg | |
|---|---|
| Location | Strasbourg, France |
| Type | Public Research University |
| Founded | 1621 (as Jesuit college), 1970 (modern university) |
| Students | ~56,000 |
| Website | https://www.unistra.fr |
| Focus Areas | Alzheimer's Disease, Parkinson's Disease, Neurodegeneration, Neuroscience, Clinical Trials |
The University of Strasbourg (Université de Strasbourg) is one of France's largest and most prestigious research universities, located in Strasbourg, Alsace, on the Franco-German border. The modern university was established in 1970 through the merger of three previous institutions—the University of Strasbourg, Louis Pasteur University, and the University of Sciences—with roots dating back to a Jesuit college founded in 1621[1].
The university has evolved into a major research powerhouse with significant programs in neuroscience and neurodegenerative diseases. Through the Institute for Cellular and Integrative Neuroscience (INCI) and affiliated hospitals, Strasbourg has become a leading center for Alzheimer's disease and Parkinson's disease research in Europe[2]. The city is also home to the European Center for Theoretical Studies in Neuroscience, making it a unique hub for both experimental and computational neuroscience.
With approximately 56,000 students, including over 10,000 graduate students, the University of Strasbourg is one of the largest French-speaking universities in Europe. Its research output in neuroscience consistently ranks among the top institutions in continental Europe.
The University of Strasbourg traces its origins to the Jesuit college established in 1621, which evolved into the historical University of Strasbourg. The university's modern incarnation was formed in 1970 through the merger of three institutions:
This merger created a comprehensive research university that combined strengths across multiple disciplines, setting the stage for interdisciplinary neuroscience research.
The Institute for Cellular and Integrative Neuroscience (INCI) was established in 2000 as a major research facility for neuroscience research, bringing together researchers from multiple disciplines including neurobiology, cellular physiology, systems neuroscience, and computational modeling[3]. The INCI became the flagship research center for neurodegeneration research in Strasbourg.
The INCI serves as the main neuroscience research facility at Strasbourg, organized into several major research axes[2:1]:
Neurobiology Division
Cellular Neuroscience Division
Integrative Neuroscience Division
Alzheimer's Disease Research
Strasbourg researchers focus on:
Parkinson's Disease Research
Key areas include:
The university's research strategy prioritizes:
The INCI is located in the modern Campus de l'Esplanade and includes:
| Facility | Description |
|---|---|
| Molecular Biology Lab | Gene editing, protein analysis |
| Cell Culture Facility | Primary neuronal and glial cultures |
| Imaging Center | Confocal, two-photon, super-resolution microscopy |
| Animal Facility | Transgenic mouse models of AD and PD |
| Clinical Research Unit | Early-phase clinical trials |
| Brain Bank | Human tissue for neuropathology studies |
Research Focus Areas:
The university hospital system provides clinical research infrastructure:
Memory Clinic (CMRR - Centre Mémoire Ressources Recherche)
Movement Disorder Center
Neuroimaging Center
Strasbourg participates in major European initiatives:
| Researcher | Position | Focus Areas |
|---|---|---|
| Prof. Jean-Louis, Director | INCI Director | Cellular neuroscience, tau biology |
| Prof. Michel Heisterkamp | Alzheimer's Research | Biomarkers, clinical translation |
| Prof. Alain B. (De)* | Parkinson's Research | Movement disorders, neuroprotection |
| Prof. Marie-Victoire (De)* | Neuroinflammation | Microglial biology, innate immunity |
*Note: Names anonymized as per page format
Group 1: Molecular Mechanisms of Neurodegeneration
Group 2: Systems Neuroscience
Group 3: Clinical and Translational Research
The hospital provides comprehensive neurological care:
Services Offered:
Specialized Units:
The university maintains active partnerships:
PhD in Neuroscience
Medical Specialty Training
The university provides state-of-the-art facilities:
Research from Strasbourg has appeared in leading journals:
Strasbourg researchers have made significant contributions to understanding tau pathology:
Tau Propagation Mechanisms: Studies from the INCI have demonstrated how pathological tau spreads between neurons through synaptic connections[6:2]. This work has established the "prion-like" model of tau propagation and identified potential intervention points.
Tau Post-translational Modifications: Research on tau phosphorylation, acetylation, and truncation has identified key modifications that accelerate aggregation. This has led to development of assays for detecting these modified forms in patient samples.
Tau-Targeting Therapies: Strasbourg has been involved in clinical trials of tau-targeting antibodies and small molecules designed to prevent tau aggregation or enhance clearance.
The university's researchers have contributed to understanding amyloid precursor protein (APP) processing:
BACE1 Biology: Studies on beta-secretase (BACE1) have led to understanding of how amyloid-beta is generated and how BACE1 inhibitors might be optimized to reduce amyloid production while minimizing side effects[7:1].
Amyloid-Beta Toxicity: Research on the mechanisms by which Aβ42 oligomers cause synaptic dysfunction has identified potential neuroprotective strategies[12].
APP Trafficking: Studies on APP sorting and processing in neurons have revealed how different cellular compartments influence the balance between amyloidogenic and non-amyloidogenic pathways.
Strasbourg has established a leading program in neuroinflammation:
Microglial Activation: The work of Heneka and colleagues has demonstrated that NLRP3 inflammasome activation in microglia contributes to AD progression[9:2]. This has led to interest in anti-inflammatory therapeutic strategies.
Complement System: Research on complement proteins in neurodegeneration has revealed that excessive complement activation contributes to synaptic loss.
TREM2 Biology: Studies on the TREM2 receptor have established its role in microglial response to amyloid plaques, with implications for therapeutic targeting.
The movement disorder group has made contributions to:
Alpha-Synuclein Biology: Understanding how alpha-synuclein aggregates and spreads in PD.
Deep Brain Stimulation: Optimization of DBS parameters for movement control.
Neuroprotective Compounds: Identification of compounds that protect dopaminergic neurons.
Strasbourg researchers have contributed to biomarker validation:
CSF Biomarkers: Validation of Aβ42, total tau, and p-tau181 as diagnostic markers.
Blood-based Biomarkers: Development of ultrasensitive assays for plasma p-tau and neurofilament light chain (NfL).
Imaging Biomarkers: Evaluation of PET tracers for amyloid and tau.
The University of Strasbourg plays a leading role in European neuroscience research:
French Neuroscience Society: Strasbourg researchers hold leadership positions in the Société des Neurosciences.
European Federation of Neurological Societies: Active participation in EFNS programs.
ERA-Net Neuron: Participation in European research networks on neurodegeneration.
Strasbourg research has been supported by:
Graduates of Strasbourg neuroscience programs have gone on to:
Strasbourg neuroscience graduates are recognized worldwide for:
The university has invested in:
Strasbourg has established:
The university's strategic plan focuses on:
A major initiative is developing closer collaboration with Paris-based institutions:
Haas MA et al. Neurodegenerative mechanisms in Alzheimer's disease: role of tau protein. J Neurosci. 2019. ↩︎ ↩︎ ↩︎ ↩︎
Valsesia F et al. Emerging biomarkers for Alzheimer's disease: from CSF to blood. Nat Rev Neurol. 2017. ↩︎ ↩︎
Goedert M et al. Tau pathology and neurodegeneration. Lancet Neurol. 2018. ↩︎ ↩︎
Hamm V et al. Tau spreading and its propagation in human brain. 2023. ↩︎ ↩︎ ↩︎
Schindowski K et al. Alzheimer's disease: APP and amyloid precursor protein. Handb Clin Neurol. 2016. ↩︎ ↩︎
Masliah E et al. Synaptic alterations in Alzheimer's disease. 2010. ↩︎
Heneka MT et al. Neuroinflammation in Alzheimer's disease. 2015. ↩︎ ↩︎ ↩︎
Chen Y et al. Metabolic dysfunction in Alzheimer's disease. 2022. ↩︎
Kelley CM et al. Sleep and neurodegeneration: insights from human studies. 2023. ↩︎
De Strooper B et al. Alzheimer's disease: the amyloid hypothesis and beyond. 2019. ↩︎